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aims: Reduced levels of free and total insulin-like growth factor 1 (IGF-I) have been 
observed in type-1 diabetes (T1D) patients. The bioavailability of IGF-I from the circula-
tion to the target cells is controlled by multifunctional IGF-binding proteins (IGFBPs). The 
aim of this study was to profile serum IGFBPs in T1D and its complications.
Design: We measured the IGFBP levels in 3662 patient serum samples from our ongo-
ing Phenome and Genome of Diabetes Autoimmunity (PAGODA) study. IGFBP levels of 
four different groups of T1D patients (with 0, 1, 2, and ≥3 complications) were compared 
with healthy controls.
results: Three serum IGFBPs (IGFBP-1, -2, and -6) are significantly higher in T1D 
patients, and these alterations are greater in the presence of diabetic complications. 
IGFBP-3 is lower in patients with diabetic complications. Analyses using quintiles revealed 
that risk of T1D complications increases with increasing concentrations of IGFBP-2 
(fifth quintile ORs: 18–60, p < 10−26), IGFBP-1 (fifth quintile ORs: 8–20, p < 10−15), and 
IGFBP-6 (fifth quintile ORs: 3–148, p < 10−3). IGFBP-3 has a negative association with 
T1D complications (fifth quintile ORs: 0.12–0.25, p < 10−5).
conclusion: We found that elevated serum levels of IGFBP-1, -2, and -6 were asso-
ciated with T1D, and its complications and IGFBP-3 level was found to be decreased 
in T1D with complications. Given the known role of these IGFBPs, the overall impact of 
these alterations suggests a negative effect on IGF signaling.
Keywords: igF-1, insulin-like growth factor 1, igF-binding proteins, diabetes mellitus, type 1, diabetic 
complications, igFBP
inTrODUcTiOn
Type-1 diabetes (T1D) patients have reduced levels of circulating free and total IGF-I with altera-
tions in the other components of the insulin-like growth factor (IGF)-axis (1–6). IGF-I exerts anti-
inflammatory and pro-survival effects on the vasculature, resulting in reduced vascular oxidant 
stress, apoptosis, and inflammatory signaling (7). A decrease in IGF-I activity has also been shown 
to promote cerebromicrovascular dysfunction (8), accelerate endothelial apoptosis, and reduce the 
TaBle 1 | characteristics of the patient population.
group n Female 
(%)
age T1D duration
a. Discovery dataset
Controls 665 53.2 22.8 ± 18.1 NA
T1D (all) 584 53.9 29.3 ± 18.5 13.2 ± 12.2
T1D no complications 453 53.4 23.2 ± 15.2 9.5 ± 8.8
T1D any complication 131 55.7 50.3 ± 12.4 26.2 ± 13.3
T1D with 1 complication 78 55.1 49.0 ± 13.6 22.1 ± 13.7
T1D with 2 complications 28 53.6 50.2 ± 9.3 31.5 ± 8.9
T1D with ≥3 complications 25 60.0 54.6 ± 10.4 32.8 ± 11.6
B. confirmation dataset
Controls 1328 55.6 22.2 ± 18.0 NA
T1D (all) 1085 51.9 30.6 ± 18.2 15.2 ± 13.2
T1D no complications 830 49.5 24.9 ± 15.8 10.8 ± 10.5
T1D any complication 255 59.6 49.0 ± 12.6 29.2 ± 11.2
T1D with 1 complication 142 59.9 45.7 ± 13.5 26.4 ± 10.8
T1D with 2 complications 62 66.1 51.6 ± 9.1 31.9 ± 11.5
T1D with ≥3 complications 51 51.0 54.8 ± 10.6 33.8 ± 9.7
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regenerative capacity of endothelium (9). The bioavailability of 
IGF-I from the circulation to the target cells is controlled by 
multifunctional IGF-binding proteins (IGFBP1–6) (5). In serum, 
about 98% of IGFs are always bound to one of the IGFBPs. In 
addition to functioning as simple carrier proteins, IGFBPs regu-
late the endocrine actions of IGFs by controlling the IGF avail-
ability for IGF receptors, whereas, locally produced IGFBPs act 
as autocrine/paracrine regulators of IGF action (10, 11). Besides, 
several IGFBPs also have IGF-independent actions, modulating 
numerous processes in the extracellular environment and inside 
the cell (10, 12–15). Interestingly, IGFBPs have been shown to 
possess anti-inflammatory function independent of IGF. In 
human endothelial cells, IGFBPs can inhibit NF-κB activity using 
their own receptors and subsequently suppress monocyte adhe-
sion to endothelial cells (16).
Several studies have indicated alterations in IGFBPs in T1D 
patients (1, 17–19); however, these studies have used relatively 
smaller sample sets. Due to large inter-individual variation in 
levels of the IGFBPs, larger sample sizes are needed to draw 
definite conclusions. Furthermore, the relationships of IGFBPs 
with accelerated micro-and macro-vascular complications are 
relatively unexplored. We measured the IGFBP-1, -2, -3, -6, and 
-7 levels in 3662 serum samples from our ongoing Phenome and 
Genome of Diabetes Autoimmunity (PAGODA)/Prospective 
Assessment in Newborns for Diabetes Autoimmunity (PANDA) 
study (20). We found that circulating levels of IGFBP-1, IGFBP-
2, and IGFBP-6 are moderately higher in T1D patients. In the 
presence of diabetic complications, circulating levels of IGFBP-1, 
IGFBP-2, and IGFBP-6 are more severely higher, and IGFBP-3 is 
moderately lower.
research Design anD MeThODs
human subjects and serum samples
All study subjects were the participants of the PAGODA/ 
PANDA study (20). Blood samples from these participants 
were collected during the subject’s visit to endocrine clinic. No 
dietary restrictions were imposed for participation in the study 
and blood collection. Presence of diabetic complications were 
determined by the attending physician/endocrinologist, based 
on eye exams, spot urinary albumin tests, and other clinical 
tests according to the ADA (21) and NFK KDOQI1 guidelines. 
The demographic characteristics for all study subjects are sum-
marized in Table 1. The study was approved by the Institutional 
Review Board at Augusta University and written informed 
consent was obtained from adult subjects and legal guardians 
for minors, in accordance with the guidelines of the Declaration 
of Helsinki. Blood samples were collected in serum separator 
tubes (BD Biosciences) and allowed to clot for 30 min at room 
temperature. Aliquots of plasma and serum were prepared 
immediately after phlebotomy into wells of 96-well plates 
(150 μl/well) to create master plates. Daughter plates were then 
created by pipetting 5–25 μl of serum/well to avoid repeated 
freeze/thaw for all samples.
1http://www2.kidney.org/professionals/KDOQI/guideline_diabetes
study Design
To minimize false-positive results, we employed a two-stage 
study design that includes a large discovery sample set and a 
larger confirmation sample set. The discovery dataset included 
665 healthy auto-antibody negative controls and 584 T1D 
patients, whereas the confirmation set included a total of 1328 
controls and 1085 T1D patients. The clinical and demographic 
information on the discovery and the confirmation datasets are 
presented in Table 1.
luminex assays
Serum protein levels were measured using Luminex bead array 
kits from Millipore (Millipore Inc., Billerica MA, USA) according 
to manufacturer’s protocol. The kit is based on sandwich immuno-
assay, which consists of dyed microspheres conjugated with a specific 
monoclonal capture antibody. Briefly, serum samples were incu-
bated with capture antibodies immobilized on polystyrene beads 
for 1 h. The beads were then washed and further incubated with 
biotinylated detection antibody cocktail for 1 h. Beads were washed 
twice to remove unbound detection antibody and then incubated 
with phycoerythrin-labeled streptavidin for 30 min. Finally, beads 
were washed and suspended in 60 μl of wash buffer. The median 
fluorescence intensities (MFI) were measured on a FlexMAP 3D 
array reader (Millipore, Billerica, MA, USA) using the following 
instrument settings: events/bead: 50, minimum events: 0, flow rate: 
60 μl/min, sample size: 50 μl, and discriminator gate: 8000–13500. 
Before profiling, the serum dilutions were optimized, by performing 
the assays at different serum dilutions to ensure that the majority of 
the data falls within the linear range of the standard curve.
statistical analyses
All statistical analyses were performed using the R language 
and environment for statistical computing (R version 2.15.1; 
R Foundation for Statistical Computing2). The comparisons 
2www.r-project.org
TaBle 2 | serum concentration of igF-binding proteins in aBn controls and T1D patients.
Protein aBn (n = 665) T1D_noc (n = 453) 1comp (n = 78) 2comp (n = 28) 3comp (n = 25)
a. Discovery dataset
IGFBP1 867 (350–2175) 1090 (554–2237) 1361 (649–3690) 2226 (1309–4813) 2272.4 (1590–3376)
(pg/ml) 1.25 (2.4 × 10−3) 1.57 (2.0 × 10−3) 2.55 (7.0 × 10−4) 2.62 (1.4 × 10−7)
IGFBP2 4.66 (1.92–11.29) 6.50 (2.83–16.8) 13.6 (5.8–28.2) 25.8 (12.0–56.7) 30.1 (11.5–52.4)
(ng/ml) 1.40 (5.6 × 10−4) 2.91 (1.4 × 10−9) 5.53 (9.6 × 10−7) 6.48 (1.5 × 10−9)
IGFBP3 15.8 (12.2–20.6) 15.2 (11.6–20.4) 12.1.(9.4–156) 12.5 (8.9–18.5) 13.5 (10.1–20.3.)
(μg/ml) 0.97 (0.24) 0.77 (1.4 × 10−6) 0.79 (0.031) 0.86 (0.15)
IGFBP6 61.8 (45.5–84.4) 67.2 (50.1–92.0) 95.7 (75.5–122.3) 111.4 (75.3–143.7) 146 (104–206)
(ng/ml) 1.09 (2.6 × 10−3) 1.55 (1.3 × 10−14) 1.80 (7.5 × 10−6) 2.36 (1.5 × 10−9)
IGFBP7 86.8 (71.1 – 108.4) 78.3 (63.53–99.8) 87.43 (67.3–108.7) 91.8 (69.8–113.4) 109.1 (75.1–139.4)
(ng/ml) 0.91 (2.6 × 10−5) 1.01 (0.87) 1.06 (0.56) 1.26 (0.023)
Protein aBn (n = 1328) T1D_noc (n = 830) 1comp (n = 142) 2comp (n = 62) 3comp (n = 51)
B. confirmation dataset
IGFBP1 861 (315–2699) 1152 (528–2913) 1418 (604–2911) 1618 (1024–3325) 2120 (1069–4709)
(pg/ml) 1.34 (4.6 × 10−7) 1.65 (7.7 × 10−7) 1.88 (2.7 × 10−5) 2.45 (2.6 × 10−7)
IGFBP2 4.2 (1.65–10.0) 8.06 (3.62–17.6) 16.1 (7.80–36.4) 23.4 (9.21–57.0) 28.3 (12.7–66.7)
(ng/ml) 1.92 (1.2 × 10−34) 3.84 (2.6 × 10−27) 5.59 (7.4 × 10−15) 6.75 (1.5 × 10−14)
IGFBP3 14.4 (12.9–18.5) 13.5 (11.9–17.4) 10.9 (10.4–15.0) 12.8 (11.1–15.6) 11.4 (8.8–15.3)
(μg/ml) 0.94 (0.031) 0.76 (2.6 × 10−4) 0.89 (0.054) 0.79 (8.1 × 10−4)
IGFBP6 60.6 (44.6–86.9) 68.6 (52.0–96.2) 94.4 (74.3–128.4) 94.4 (68.0–139.4) 131.6 (86.8–193.4)
(ng/ml) 1.14 (1.2 × 10−7) 1.56 (1.5 × 10−15) 1.56 (1.9 × 10−6) 2.17 (2.2 × 10−13)
First row: mean (25th–75th percentile); second row: fold change vs. ABN (p-value).
ABN, antibody negative controls; T1D_NoC, T1D, no complications; 1Comp, T1D any complication; 2Comp, T1D with 2 complications; 3Comp, T1D with ≥3 complications.
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between group means were made by ANOVA (for ≥3 groups) 
followed by pair-wise comparisons using Bonferroni post hoc 
testing. The statistical significance of differences was set at 
p < 0.05. The effect of age on the serum levels of each candidate 
molecule was determined using a linear regression of protein 
concentration with age as covariate on data stratified by sex 
and disease status. To examine the relationships between 
disease status and the serum protein levels, logistic regression 
was used by including age and sex as covariates. To assess the 
odds ratios of having T1D or complications at different levels 
of each protein, subjects were divided into five quintiles based 
on protein levels. The cutoff protein levels for these quintiles 
were then used to count controls and cases in each quintile. 
The first quintile was used as reference, and odds ratios of 
having disease was calculated for upper four quintiles using 
Pearson’s chi-squared test with Yates’ continuity correction. 
The chi-squared test for trend in proportions was used to 
calculate the p-value of overall trend. Risk scores (equal to 
odds ratio) were assigned to each subject based on individual 
protein levels. For a combination of proteins, the combined 
risk score of each subject was calculated by simply adding risk 
score from multiple proteins. The odds ratios of having disease 
were calculated for upper four groups against the reference 
group as mentioned above.
resUlTs
Serum levels of five IGFBPs were measured in T1D patients and 
healthy controls to discover the alterations associated with T1D 
and/or its complications. To minimize false-positive results, a 
total of 3662 serum samples were divided into a discovery phase 
(1249 samples) and a confirmation phase (2413 samples). Clinical 
characteristics of the patient population in both sets are presented 
in Table 1. In the discovery phase, five IGFBP proteins (IGFBP-1, 
-2, -3, -6, and -7) were measured using a smaller sample set [665 
antibody negative controls (AbN) controls; 584 T1D subjects]. 
Significant changes were observed in the levels of IGFBP-1, -2, -3, 
and -6, therefore, these four proteins were moved forward to the 
confirmation phase using a larger cohort of samples (1328 AbN 
controls; 1085 T1D subjects).
igF-Binding Proteins are significantly 
altered in T1D and its complications
The status of diabetic complications in T1D subjects was captured 
from the medical charts, and the subjects with and without 
complications were examined separately. The protein levels were 
examined by separating the T1D patients into four groups (T1D 
without complications and T1D with 1, 2, or ≥3 complications). 
Comparison of the mean circulating levels between T1D patients 
without complications and controls revealed significant differ-
ences for two proteins in both discovery and confirmation sets 
(IGBP-1: 1.25- and 1.34-fold; IGFBP-2: 1.40- and 1.92-fold). 
Moderate changes (3–14%) were observed in the levels of IGFBP-
3, IGFBP-6, and IGFBP-7 (Table 2).
Comparison of the mean circulating levels between T1D 
patients with complications and controls revealed greater changes 
in IGFBP-2 (3–6-fold), IGFBP-1 (1.5–2.5-fold), and IGFBP-6 
(1.5–2.5-fold) in both discovery and confirmation sample sets, 
whereas the levels of IGFBP-3 were moderately but significantly 
reduced (~0.8-fold). Furthermore, serum levels of IGFBP-1, -2, 
TaBle 3 | logistic regression analysis using protein concentration, before and after adjusting for covariates.
Test Unadjusted adjusted
Protein Or 95% ci Or 95% ci
a. Discovery dataset
T1D_NoC vs. ABN IGFBP1 1.196 (1.060–1.350) 1.221 (1.077–1.385)
IGFBP2 1.296 (1.119–1.505) 1.280 (1.104–1.489)
IGFBP3 0.929 (0.823–1.049) 0.929 (0.821–1.049)
IGFBP6 1.220 (1.071–1.392) 1.264 (1.089–1.470)
IGFBP7 0.762 (0.670–0.864) 0.754 (0.661–0.857)
1Comp vs. ABN IGFBP1 1.359 (1.094–1.69) 2.443 (1.801–3.372)
IGFBP2 2.474 (1.832–3.41) 2.365 (1.632–3.520)
IGFBP3 0.568 (0.449–0.714) 0.478 (0.357–0.636)
IGFBP6 2.940 (2.215–3.971) 1.838 (1.285–2.676)
IGFBP7 1.024 (0.802–1.319) 0.794 (0.590–1.069)
2Comp vs. ABN IGFBP1 1.826 (1.303–2.576) 4.095 (2.499–7.167)
IGFBP2 3.936 (2.498–6.506) 4.757 (2.641–9.522)
IGFBP3 0.627 (0.450–0.889) 0.523 (0.339–0.811)
IGFBP6 3.588 (2.360–5.702) 3.561 (2.016–6.776)
IGFBP7 1.183 (0.796–1.803) 1.011 (0.630–1.668)
3Comp vs. ABN IGFBP1 1.885 (1.314–2.722) 8.153 (3.895–20.107)
IGFBP2 5.013 (3.003–8.975) 8.421 (3.728–23.227)
IGFBP3 0.724 (0.508–1.065) 0.668 (0.412–1.071)
IGFBP6 7.460 (4.392–13.915) 10.06 (4.595–26.378)
IGFBP7 2.047 (1.316–3.20) 1.833 (1.064–3.323)
B. confirmation dataset
T1D_NoC vs. ABN IGFBP1 1.237 (1.134–1.351) 1.305 (1.193–1.43)
IGFBP2 1.801 (1.632–1.993) 1.782 (1.614–1.972)
IGFBP3 0.905 (0.825–0.990) 0.915 (0.834–1.001)
IGFBP6 1.289 (1.171–1.421) 1.222 (1.1–1.36)
1Comp vs. ABN IGFBP1 1.427 (1.198–1.712) 2.283 (1.824–2.895)
IGFBP2 3.151 (2.568–3.906) 3.444 (2.716–4.432)
IGFBP3 0.780 (0.690–0.883) 0.713 (0.616–0.835)
IGFBP6 2.881 (2.293–3.654) 1.725 (1.324–2.283)
2Comp vs. ABN IGFBP1 1.578 (1.215–2.087) 2.942 (2.053–4.362)
IGFBP2 4.250 (3.136–5.905) 4.364 (3.05–6.49)
IGFBP3 0.875 (0.738–1.109) 0.751 (0.581–1.075)
IGFBP6 2.883 (2.079–4.055) 1.524 (1.034–2.297)
3Comp vs. ABN IGFBP1 2.000 (1.468–2.804) 3.985 (2.607–6.408)
IGFBP2 5.144 (3.630–7.551) 6.396 (4.044–10.844)
IGFBP3 0.814 (0.691–1.010) 0.656 (0.504–0.928)
IGFBP6 6.408 (4.312–9.947) 3.694 (2.3–6.159)
ABN, antibody negative controls; T1D_NoC, T1D no complications; 1Comp, T1D any complication; 2Comp, T1D with 2 complications; 3Comp, T1D with ≥3 complications.
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and -6 were increased with increase in number of complications 
(Table 2).
influence of covariates on serum Protein 
levels
We next examined the potential influence of various covariates 
on serum protein levels in controls and T1D patients with or 
without complications. Significant correlations with age and sex 
were observed. Therefore, logistic regression analyses were car-
ried out using protein concentration after adjusting for age and 
sex. In these regression analyses, IGFBP-1, -2, -6, and -7 showed 
moderate but significant associations with T1D (Table  3). 
Whereas, in T1D with complications IGFBP-1, -2, -3, and -6 
showed highly significant associations (IGFBP-1: OR = 2.4, 4.1, 
8.2; IGFBP-2: OR = 2.4, 4.8, 8.4; IGFBP-3: OR = 0.48, 0.52, 0.67; 
IGFBP-6: OR =  1.8, 3.6, 10, for 1Comp, 2Comp and 3Comp 
groups, respectively) (Table  3). These results suggest that the 
association between T1D complications and these serum pro-
teins cannot be accounted for by the covariates examined in this 
study. These findings could be confirmed using an independent 
confirmation dataset.
analysis of serum Protein levels Using 
age Matched Dataset
Since the healthy control and T1D without complication cohorts 
were fairly large, we decided to censor these groups to better age 
match with complication patients. Boxplots depicting the distri-
bution of the protein levels in matched data are shown in Figure 1. 
A clear increasing trend was observed for IGFBP-1, IGFBP-2, and 
IGFBP-6 with increase in number of complications. Since similar 
findings were observed in both discovery and confirmation sets, 
we merged these datasets for further analyses.
FigUre 1 | Distribution of serum protein levels in age matched datasets. Boxplots depict the distribution of the protein levels in five different groups (ABN, 
antibody negative controls; T1D_NoC, T1D no complications; 1Comp, T1D with any complication; 2Comp, T1D with 2 complications; 3Comp, T1D with ≥3 
complications). A clear increasing trend was observed for IGFBP-1, IGFBP-2, and IGFBP-6 with increase in number of complications. *p < 0.05.
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risk of T1D and its complications with 
igFBP alterations
The risk of having diabetic complications at different levels of 
serum proteins was examined by computing the odds ratios at 
five quintiles. Four different groups of T1D patients (0, 1, 2, ≥3 
complications) were compared with healthy controls. For these 
analyses, cutoff values for each protein were determined by divid-
ing the patient group into five quintiles. These cutoff values were 
used to assign the healthy controls and patients into five different 
groups. Odds ratios for the top four quintiles were computed using 
bottom quintile as reference (Figure 2A). For T1D-noComp, the 
strongest association is observed with IGFBP-2 (p-trend <10−35), 
which has an OR of 18.6, for the fifth quintile. IGFBP-3 has the 
second strongest association (p-trend <10−19) with OR of 0.18 for 
the top quintile. IGFBP-1 is the third best protein with maximum 
OR of 5.5 (p-trend <10−18).
For T1D complications, the strongest association is observed 
with IGFBP-2 (p-trend  =  10−27–10−35) followed by IGFBP-1 
(p-trend =  10−16–10−20), IGFBP-3 (p-trend =  10−05–10−15), and 
IGFBP-6 (p-trend = 10−04–10−13). These analyses clearly suggest 
that risk of having complication increases with increasing IGFBP-
1, -2, and -6 and with decreasing IGFBP-3 levels (Figure 2A).
Protein combinations Define Patients at 
high risk of Developing T1D and 
complications
Since multiple IGFBPs are associated with complications, we 
attempted to examine the combined effect of these proteins. 
For this purpose, we calculated risk score of each subject by 
adding the quintile odds ratios from individual proteins and 
then examined association between disease and the risk scores. 
The combinations improved the highest OR values as well as the 
FigUre 2 | risk of T1D and its complications with igFBP alterations. Four groups (T1D_NoC, 1Comp, 2Comp, and ≥3Comp) were compared to ABN 
controls. Individual proteins (a) and protein combinations (B) were used to assess the odds ratios of having T1D or complications at different protein levels. All 
subjects were divided into five quintiles based on protein levels. The first quintile was used as reference, and odds ratios of having disease was calculated for upper 
four quintiles. The chi-squared test for trend in proportions was used to calculate the p-value of overall trend. Analyses using quintiles revealed that risk of T1D and 
complications increases with increasing concentrations of IGFBP-2, IGFBP-1, and IGFBP-6, whereas, IGFBP-3 has a negative association with T1D complications. 
The open bar represents the first quintile as reference (OR = 1). From left to right, each of the other four solid bars represent second to fifth quintiles.
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proportion of T1D subjects with the highest OR (Figure 2B). The 
best three protein model was IGFBP-1 + IGFBP-2 + IGFBP-6, 
which improved the ORs associated with the third to fifth quin-
tile (third to fifth quintile ORs: noComp = 7–19; 1Comp = 9–25; 
2Comp = 17–67; 3Comp = 28–196). Four-protein model fur-
ther improved the highest OR over the three protein models 
(third to fifth quintile ORs: noComp = 7–28; 1Comp = 11–25; 
2Comp = 20–110; 3Comp = 32–184) (Figure 2B).
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DiscUssiOn
This study was undertaken to profile IGFBPs in T1D and its 
complications using a large patient cohort. We found moderate 
changes in the levels of several IGFBPs in T1D and more severe 
alterations in the presence of diabetic complications. An increase 
in IGFBP-1, IGFBP-2, and IGFBP-6 levels along with decrease in 
IGFBP-3 was significantly associated with the presence of diabetic 
complications. These findings have potential clinical implica-
tions, as IGFBP complexes may serve as better therapeutic targets 
to ameliorate the decreased IGF signaling in T1D, potentially to 
prevent diabetic complications.
Insulin-like growth factor 1-binding protein-3 prolongs IGF 
half-life in the circulation and serves as the main carrier of IGF 
to the cell-surface. On the other hand, IGFBP-1 and IGFBP-2 
have a well-known role in metabolic regulation, maintaining 
blood glucose levels, insulin sensitivity, glucose intolerance, and 
hyperinsulinemia (22–24). In addition, IGF-independent actions 
of IGFBPs are an emerging area of research.
Insulin-like growth factor 1-binding protein-3 is the most 
important carrier of IGF, which is bound to about 75% of IGF in 
the blood circulation and promotes somatic growth by increasing 
the IGF-I access to its cellular receptors. It is well established that 
high levels of IGFBP-3 are associated with growth stimulation 
(25). In our study, we found a significant association between 
the decreased levels of IGFBP-3 and T1D complications (second 
quintile OR =  0.67–0.93; third quintile OR =  0.29–0.8; fourth 
quintile OR = 0.15–0.53; fifth quintile OR = 0.13–0.36). IGFBP-3 
has also been shown to have IGF-independent functions and acts 
as an anti-inflammatory molecule. In human aortic endothelial 
cells, IGFBP-3 inhibits TNF-α, CRP, and high glucose-induced 
NF-κB activity and subsequently suppresses monocyte adhesion 
to endothelial cells through the IGFBP-3 receptor (16). Reduced 
levels of IGFBP-3 in T1D complications may result in suppression 
of its anti-inflammatory functions, and, therefore, IGFBP-3 may 
present itself as a therapeutic target for events occurring during 
the development of complications. Also, in a recent study, it has 
been shown that IGFBP-3 inhibits retinal endothelial cell apopto-
sis through activation of an IGFBP-3 receptor in a hyperglycemic 
environment (26). IGFBP-3 increases endothelial NO synthase 
expression in human endothelial progenitor cells leading to NO 
generation and provides cytoprotection following vascular injury 
(27). Our study and accumulating evidences in recent literature 
confirm the role of IGFBP-3 in diabetic complications, however 
further studies are needed to elucidate the precise mechanisms.
Unlike IGFBP-3, the actions of other IGFBPs are very differ-
ent. IGFBP-1 levels are low during the growth phase but increase 
several-fold during prolonged catabolic states due to growth 
inhibition. IGFBP-1 concentrations are dynamically regulated 
in response to nutritional status (13). The plasma insulin levels 
are inversely correlated with the IGFBP-1 levels. Inhibition of 
IGFBP-1 transcription by insulin is mainly conferred by insulin 
response element in the IGFBP-1 promoter region. In our study, 
we found significantly higher levels of IGFBP-1 in both T1D with 
and without complications as compared to controls; however, the 
differences were larger in T1D with complications (second quintile 
OR = 2–6; third quintile OR = 4–8; fourth quintile OR = 4–23; 
and fifth quintile OR = 5–19). Poor glycemic control in T1D is 
associated with elevated serum IGFBP-1 levels and reduced serum 
IGF-I levels, particularly where microvascular complications are 
present (9). Increasing age is accompanied by a further increase 
in IGFBP-1 levels in both T1D and T2D subjects. This age- 
and diabetes-dependent increase in IGFBP-1 and subsequent 
decrease in IGF-I activity accelerate endothelial cell death and 
reduce the regenerative capacity of these cells, offering a possible 
mechanism for the development of vascular complications (9).
In our study, the largest increase was observed in the levels of 
IGFBP-2 (~2-fold in T1D alone and ~4-fold in T1D with com-
plications). Quintile analyses revealed increased risk of T1D and 
complications with increase in IGFBP-2 levels (second quintile 
OR = 3–4; third quintile OR = 6–55; fourth quintile OR = 8–38; 
and fifth quintile OR  =  18–60). IGFBP-2, the major IGFBP 
expressed in infancy, has been linked to childhood obesity and 
is the predominant IGFBP produced from adipocytes. IGFBP-2 
is known to act as an important link between nutrition, growth, 
and metabolism, but its association with diabetic complications 
remains poorly understood. A recent study demonstrates that 
IGFBP-2 is a predictor of longitudinal deterioration of renal 
function in type 2 diabetes (28). Another study in T2D patients 
revealed that baseline concentrations of IGFBP-1 and IGFBP-2 are 
associated with longitudinal elevation in HDL-cholesterol (29).
Insulin-like growth factor 1-binding protein-6 is unique 
among all IGFBPs because it has a preferential affinity for IGF-II. 
Inhibition of IGF-II actions is the major action of IGFBP-6; 
however, a number of studies suggest IGF-independent actions 
of IGFBP-6. A recent study using a non-IGF-II binding analog 
of IGFBP-6 has shown IGF-II-independent roles for IGFBP-6 in 
inhibition of cellular proliferation (30). In our study, we found 
increased IGFBP-6 levels in T1D complications.
Systemic administration of free IGF-I has restricted therapeutic 
potential due to instability in the circulation and side effects. On 
the other hand, IGFBPs can produce more stable IGF signaling in 
the vascular compartments. Studies have shown that IGF-I/cou-
pled with IGFBP-3 affords more efficient protection from insulitis, 
β-cell destruction, and T1D than IGF-I and has a potential as a 
prophylactic therapy in the prevention of autoimmune T1D (31).
In conclusion, we found that elevated serum levels of IGFBP-1, 
-2 and, -6 were associated with T1D, and its complications and 
IGFBP-3 level was found to be decreased in T1D with complica-
tions. As IGFBPs are proving to be better therapeutic potential 
in metabolic disorders as compared to IGF, studies in this direc-
tion will help to define both diagnostic and therapeutic roles for 
IGFBPs in T1D and its complications. Also, these data provide us 
a foundation to explore IGF-independent mechanisms of IGFBPs 
during the development of diabetes and its complications.
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